Domain Therapeutics

33 articles about Domain Therapeutics

•  Domain Therapeutics Receives a Single Digit Multimillion Development Milestone Payment from Merck for M1069 Clinical Development in Immuno-Oncology

  6/28/2022

  Domain Therapeutics, today announced that it obtained a single digit multimillion milestone payment from Merck as part of the €240m ($261m) milestone payments and undisclosed royalties collaboration and license partnership signed in 2017.

• Domain Therapeutics Appoints Dr Xavier Leroy as Chief Scientific Officer

  6/13/2022

  Domain Therapeutics, a biopharmaceutical company specializing in the research and development of innovative drugs targeting G Protein-Coupled Receptors in immuno-oncology, announced that it is strengthening its scientific team with the appointement of Dr Xavier Leroy as CSO.

• 

  Money on the Move: SwanBio, Remix, Locus, Mirvie and More

  5/18/2022

  Recent funding saw support for a platform that selectively degrades DNA, software to help read mammograms and a company using corn genetics to develop cancer-targeting viruses.

• Domain Therapeutics Raises $42m Series A Financing

  5/10/2022

  Domain Therapeutics announced the closing of a US $42m series A financing round co-led by Panacea Venture, CTI Life Sciences and 3B Future Health Fund, and joined by adMare BioInnovations, Schroders Capital, Omnes, Turenne Capital, Theodorus, Viva BioInnovator and existing investor Seventure Partners.

• Domain Therapeutics is granted European and US patent for biosensors assessing GPCR trafficking

  2/4/2020

  Unique feature of bioSens-All™ technology enables discovery of therapeutics for pathologies linked to GPCR mistrafficking

• Domain Therapeutics secures €6 million ($6.7M) debt financing

  1/13/2020

  GPCR company will expand proprietary portfolio and prepare next financing round

• Domain Therapeutics and Pr Michel Bouvier (IRIC Montreal) receive the RSRI award for bioSens-All™ project at ADRIQ-RCTi Innovation Prize gala

  12/17/2019

  GPCR biosensor technology, developed via support of CQDM, Merck and Pfizer, recognized as breakthrough approach in GPCR characterization

• Domain Therapeutics reaches two milestones in multi-target research collaboration with Boehringer Ingelheim

  9/30/2019

  Less than one year after signing agreement, the GPCR expert has reached key discovery milestones in two independent projects

• Domain Therapeutics invests in Ermium Therapeutics to develop first-in-class CXCR4 candidate for autoimmune diseases

  9/11/2019

  G Protein Coupled Receptor (GPCR) expert will invest up to €3M ($3.3M) to unlock the therapeutic potential of breakthrough asset

• Domain Therapeutics appoints Xavier Leroy as chief technology officer

  7/8/2019

  Drug discovery expert will be responsible for developing Domain’s platforms and driving technology-based projects to support Domain’s development and growth

• Domain Therapeutics strengthens its scientific advisory board with leading GPCR and disease experts

  6/24/2019

  Domain Therapeutics announces the appointment of world-renowned GPCR and drug discovery and development experts to its Scientific Advisory Board (SAB): Pr. Silvio Gutkind, Pr. Morley Hollenberg and Pr. Brigitte Kieffer.

• Domain Therapeutics appoints Sylvie Ryckebusch to board of directors

  6/12/2019

  Seasoned business executive will bring important insights in licensing strategy and contribute to Domain’s next phase of development

• European Venture Capital Firm Seventure Partners renews its support to Domain Therapeutics and invests €3.5M ($3.9M) to prepare next growth phase

  5/28/2019

  Domain Therapeutics announces that it has secured a €3.5M investment from existing shareholder Seventure Partners, to accelerate its next growth phase.

• DOMAIN THERAPEUTICS SIGNS A MULTI-TARGET RESEARCH COLLABORATION AND LICENSE AGREEMENT WITH BOEHRINGER INGELHEIM

  12/4/2018

  Domain Therapeutics’ unique platform technologies will be used to identify novel treatment approaches for neuropsychiatric diseases

• Domain Therapeutics And Pfizer Enter Into Collaboration Agreement On bioSensAll

  4/25/2017

• Merck KGaA Release: Company Announces Research Collaboration With Domain Therapeutics In Immuno-Oncology

  1/23/2017

• Domain Therapeutics Grants Alkermes A Non-Exclusive License For Its G Protein-Coupled Receptor BioSens-All Technology

  12/14/2016

• Domain Therapeutics And Medicxi Launch Mavalon Therapeutics, Aimed At Halting The Progression Of Parkinson's Disease

  10/18/2016

• Domain Therapeutics, Université de Montréal, Iricor And McGill University Extend Licensing And Partnership Agreement On G Protein-Coupled Receptor Biosensor Technology

  9/27/2016

• Domain Therapeutics Launches Specific Purpose Vehicle Kaldi Pharma To Harness The Potential Of Its Adenosine Programs

  3/4/2015